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Activation-induced cytidine deaminase (AID) is essential for somatic hypermutation and
class switch recombination of immunoglobulin (Ig) genes during B cell maturation and
immune response. Expression of AID is tightly regulated due to its mutagenic and recom-
binogenic potential, which is known to target not only Ig genes, but also non-Ig genes,
contributing to lymphomagenesis. In recent years, a new epigenetic function of AID and
its link to DNA demethylation came to light in several developmental systems. In this
review, we summarize existing evidence linking deamination of unmodified and modified
cytidine by AID to base-excision repair and mismatch repair machinery resulting in passive
or active removal of DNA methylation mark, with the focus on B cell biology.We also discuss
potential contribution of AID-dependent DNA hypomethylation to lymphomagenesis.
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DYNAMIC NATURE OF METHYLOME DURING B CELL
DEVELOPMENT
Epigenetic mechanisms of regulation including histone modifi-
cations, non-coding RNA-mediated gene regulation, chromatin
remodeling, and DNA methylation (1) play an important role in
B cell differentiation and the antibody response (2). DNA methy-
lation is essential during X-chromosome inactivation, imprinting,
and tissue differentiation (3, 4). This epigenetic modification refers
to the addition of a methyl group at the C5 position of cytosine
(C), mostly when C is bound to guanine (G) creating a CpG
site in mammalian organisms (5, 6), with less common non-
CpG methylation detected in embryonic stem cells (ESCs) and
brain tissue (7, 8). The addition of the methyl group is catalyzed
by the family of DNA methyltransferases (DNMTs) (9), whereas
DNA demethylation can be a passive or an active process. Passive
demethylation occurs when methylC (mC) mark is not faithfully
reproduced either during replication or due to DNA damage, while
active demethylation requires the action of enzymes and can be
replication-independent (10,11). However, the molecules involved
in the 5-methylC (5mC) active demethylation are still not clearly
defined (see below). Several studies have investigated the DNA
methylation landscape in B cells and the role of the DNA methy-
lome in B cell development. Ji et al. demonstrated in a mouse
model using Comprehensive High-throughput Array-based Rela-
tive Methylation analysis (CHARM) (12) that lymphoid commit-
ment requires more DNA methylation than myeloid lineage with
Abbreviations: BCR, B cell receptor; BER, base-excision repair; BL, Burkitt
lymphoma; CSR, class switch recombination; DLBCL, diffuse large B cell lym-
phoma; DNMTs, DNA methyltransferases; DSBs, double strand DNA breaks; EMT,
epithelial–mesenchymal transition; ESC, embryonic stem cells; FL, follicular lym-
phoma; GCBs, germinal center B cells; Ig, immunoglobulin; iPSCs, induced pluripo-
tent stem cells; MMR, mismatch repair; NBs, naïve B cells; PGCs, primordial germ
cells; SHM, somatic hypermutation; TLR, toll-like receptor.
myeloid skewing of lineages in DNMT1 hypomorphic animals.
Loss of methylation predominates during progression of Multi-
potent Progenitors (MPPs) to Common Lymphoid Progenitors
(CLPs) (13, 14). During transition from naïve B cells (NBs) to ger-
minal center B cells (GCBs), occurring in the secondary lymphoid
organs after T cell-mediated activation, there is marked demethyla-
tion of the genome (15, 16). Memory and plasma cells display DNA
methylation patterning very similar to GCBs, although the three
subpopulations of B cells differ substantially at the transcriptional
level (16). The use of the DNA demethylating agent Decitabine
results in complete abrogation of the GCs, while preserving the
primary follicles (15), underscoring an important biological role
of methylation in B cell development. The fact that entrance of
NBs into the GC reaction is characterized by marked upregu-
lation of DNMT1 and simultaneous hypomethylation of many
genomic loci suggests yet unknown mechanisms of passive or
active demethylation after B cell activation. In this review, we
would like to explore the potential role of activation-induced cyti-
dine deaminase (AID) in modifying the methylome of mature B
cells. We will present and analyze large amount of conflicting evi-
dence that accumulated up to date linking AID with epigenetic
modifications during development and B cell differentiation.
FUNCTION OF AID IN B CELL DEVELOPMENT
NBs enter the GC reaction and undergo marked changes in
transcriptional program, including dramatic upregulation of the
enzyme AID (or AICDA), a member of the APOBEC family of
cytidine deaminases that is required for both somatic hypermu-
tation (SHM) and class switch recombination (CSR) (17–19).
SHM results in the introduction of somatic mutations in the
rearranged V(D)J region of the Ig genes (IgV) in order to gen-
erate antibodies with high affinity antigen binding sites (20, 21).
Additionally, GCBs undergo a process of CSR of the constant
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region of the immunoglobulin (Ig) heavy chain (CH), generat-
ing isotypes with different immunological functions but the same
antigen-specificity (22–24). Both SHM and CSR are initiated by
the deaminase activity of AID, which is able to convert deoxy-
cytosines (dC) into deoxyuracils (dU) in a single-stranded DNA,
producing dU:dG mismatches that are removed by base-excision
repair (BER) and mismatch repair (MMR) pathways (19, 25, 26).
AID can also deaminate 5mC to thymine (T), although with
less efficiency (27). AID is expressed in B cells in a stage spe-
cific manner during transition of NB through the GCs (28). NBs
integrate signals through B cell receptor (BCR) and Toll-like recep-
tors (TLRs), along with stimulation via surface receptors, such
as CD40 and cytokine receptors, to initiate the NF-κB-mediated
AID transcription (29). In the secondary lymphoid organs, AID is
expressed in a subpopulation of dark and outer zone GCBs and
in large extrafollicular B cells, which have evidence of CD40 and
BCR stimulation (28), and is downregulated after differentiation
of GCBs to memory and/or plasma cells (30, 31). In addition,
viral infection of B cells can induce expression of AID (31–34).
Ig genes are the main targets of AID, with a mutation rate of
10−4 to 10−3/bp per generation (35, 36). Nonetheless, non-Ig
genes such as BCL6, CD79A, CD79B, or CD95 are also suscep-
tible to AID-mediated mutations (37–40). Moreover, Liu et al.
reported that around 25% of the highly expressed genes in GCBs,
including Bcl6, Cd83, Pim1, Pax5, and Myc among others, experi-
enced AID-mediated deamination and low-level of SHM (41).
The authors demonstrated that these non-Ig genes were pro-
tected from mutations in normal B cells due to the activity of
high-fidelity BER factors. Besides, they observed that there was
correlation between target regions of AID and sites of chromo-
somal translocations and deletions present in human lymphomas
(41). They proposed that malfunction of repair machinery could
lead to AID-mediated mutations and chromosomal instability, and
finally to tumorigenesis. In line with these results, Yamane et al.
performed chromatin immunoprecipitation sequencing (CHIP-
seq) for AID in ex vivo activated B cells and proposed that AID
was recruited genome-wide by stalled PolII polymerases, induc-
ing low-level of hypermutation in those AID-targeted genes (42).
Importantly, these findings provided insight into the role of AID
in lymphomagenesis.
EVIDENCE LINKING AID TO DNA DEMETHYLATION
There is a body of accumulating evidence linking AID to genome-
wide epigenetic changes, and specifically to DNA demethyla-
tion (43). A significant discovery has been made in recent years
that implicated AID in DNA demethylation in three paradigms:
epigenetic reprogramming in heterokaryons using mouse ESCs,
demethylation in zebrafish, and global demethylation in mouse
primordial germ cells (PGCs) (44–46). The capacity of AID to
deaminate 5mC in a single-stranded DNA was established in vitro
(27), although the efficiency of 5mC deamination by AID was 5–10
times lower compared to unmethylated-C (47). The same report
by Morgan et al. (27) demonstrated that AID mRNA was highly
expressed in oocytes and ovaries, and moderately expressed in
pluripotent cells (embryonic germ cells, ESCs, and PGCs), which
can undergo epigenetic reprograming. Those results indicated
that expression of AID was not restricted to activated B cells in
the GCs of lymphoid organs and prompted the authors to sug-
gest that the upregulation of AID (and other members of the
APOBEC family) in pluripotent tissues could play a role in the
epigenetic reprogramming during development. Rai et al. followed
that hypothesis and presented the first evidence of the epigenetic
role of AID (45). They proposed an active DNA demethylation
mechanism in zebrafish embryos in which 5mC was converted to
T through the cytosine deaminase activity of AID and the sub-
sequent G:T mismatch was repaired by the thymine glycosylase
methyl-CpG binding domain protein 4 (MBD4). The injection
of methylated DNA (M-DNA) at the single-cell stage induced
genome-wide demethylation in zebrafish embryos, allowing the
analysis of epigenetic changes in both the injected M-DNA and
the bulk genome. After knockdown of AID/APOBEC enzymes
using anti-sense morpholino-modified oligonucleotides there was
a reduction in demethylation. On the contrary, overexpression of
AID (or APOBEC2A/B) and MBD4 induced DNA demethylation
of M-DNA and the embryo genome (45).
Thereafter, the production of interspecies heterokaryons
(mouse ESCs fused to primary human fibroblasts using polyethyl-
ene glycol) allowed the identification of AID-mediated demethy-
lation as a key process for nuclear reprogramming toward pluripo-
tency (44). Transfection experiments with small interference RNAs
(siRNAs) for mouse and human AID mRNA 24 h before fusion
inhibited expression of the ESC-specific genes OCT4 and NANOG
and reduced the CpG demethylation in the promoter of those
genes. The transient overexpression of the human AID protein
before siRNA transfection returned NANOG promoter demethy-
lation and gene expression to normal levels and partially rescued
OCT4 demethylation and gene expression.
Primordial germ cells also undergo a process of epigenetic
reprogramming, including DNA demethylation, which is pivotal
for the acquisition of pluripotency during the germ line devel-
opment (48, 49). Popp et al. demonstrated, on a genome-wide
scale, that the genome from fully reprogramed PGCs at E13.5 was
extensively hypomethylated and that the absence of AID increased
DNA methylation levels, mainly in introns and repetitive elements
and also in exons, but not in the promoter regions (46). Impor-
tantly, the epigenetic effect of AID on the genome of PGCs was
confirmed by two independent techniques: bisulfite next gen-
eration sequencing (BS-Seq) and Sequenom MassARRAY. This
finding of DNA hypermethylation in cells from Aicda−/− mice
was restricted to PGCs since the genome-wide methylation levels
remained unaffected in the fetus, the placenta, and the sperm. A
biological process required during embryogenesis is the epithelial–
mesenchymal transition (EMT), in which epithelial cells acquire
a mesenchymal phenotype characterized by increased migratory
capacity and invasiveness and production of extracellular compo-
nents (50). In addition, EMT is a driving force for tumor metastasis
(51). AID is upregulated in epithelial cells during inflammation
in vivo (52–54) and by inflammatory factors in vitro (55, 56) and
was shown to be required for the EMT in both normal mam-
mary epithelial cells and breast cancer cell lines (55). Knockdown
of AID in epithelial cell lines blocked the upregulation of SNAI2,
ZEB1, and ZEB2, which are master regulator genes for EMT. Those
genes inhibited by AID-deficiency presented high levels of methy-
lation in the CpG islands associated with the promoters and were
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re-expressed in the presence of the demethylating agent 5-aza-
2′deoxycitidine, indicating that AID regulated the transcription of
EMT-associated genes through DNA demethylation (55).
The in vitro generation of induced pluripotent stem cells
(iPSCs) by Yamanaka’s group from adult somatic cells through the
addition of four transcription factors: OCT4, KLF4, SOX2, and c-
MYC (57) opened new possibilities for regenerative medicine and
autologous therapies. AID was identified as a critical factor for the
initiation of mouse embryonic fibroblasts (MEFs) reprogramming
to iPSCs (58). Inhibition of AID expression with shRNAs during
the first 72 h after reprogramming induction reduced the number
of iPSCs colonies. In addition, rescue experiments with a con-
struct containing a catalytically deficient version of AID (E58Q)
demonstrated that the deaminase activity of AID was required
for the induction of iPSCs (58). However, experiments performed
by different groups with Aicda−/− mice challenged this conclu-
sion because AID-deficient fibroblasts were able to generate iPSCs,
although with different kinetics depending on the concentration
of virus supernatant, the transfection plasmids, and the culture
conditions, including the number of cell passages (59–61). Inter-
estingly, Kumar et al. observed that cells from Aicda−/− mice
generated iPSCs, but failed to stabilize the expression of pluripo-
tency genes after 3 weeks of culture (59), a phenomenon that cor-
related with genome hypermethylation in reprogramming cells,
especially near RGYW motifs. Additionally, genes that were upreg-
ulated later during reprogramming (Rex1, Gdf3, Dnmt3l, Dnmt1,
Apobec1, Cbx7, and Zfp96) presented higher levels of methylation,
both by RRBS and Sequenom MassArray, and were not expressed
in the absence of AID (59). The authors proposed that AID was
essential for the late phase of reprogramming, which is character-
ized by the genome-wide erasure of DNA methylation to stabilize
a pluripotent phenotype (62).
Although AID is highly expressed in the GCBs and is respon-
sible for the generation of high affinity antibodies through the
induction of SHM and CSR (20, 43), to date only few studies have
addressed the epigenetic role of AID in activated B cells (15, 63).
An important link between SHM in B cells and DNA hypomethy-
lation has been made by several studies (19, 64, 65). Endonuclease
sensitivity sites within the loci containing CpG nucleotides and
located close to J-C intronic enhancers are methylated in somatic
cells, but are demethylated in B cells (66–68). Jolly et al. stud-
ied DNA methylation and SHM in Jκ5 region, due to the high
density of CpGs and high level of SHMs in those loci. They
demonstrated that the locus was heavily methylated in mouse
tail DNA, whereas it was totally demethylated in the GCBs from
Peyer’s patches (64). Studying the Igκ transgene and analyzing the
Jκ5 locus they were able to demonstrate that B cells contained a
mixture of loci with different state of methylation. Most impor-
tantly, the degree of demethylation correlated with the burden
of SHM: only demethylated loci contained detectable mutations.
This finding led the authors to conclude that transcription and
demethylation are requited for SHM, and thus for AID targeting.
Our current view is that it is equally possible that demethylation
is a consequence of the deaminase activity of AID, which intro-
duces mutations that are subsequently repaired. Hypomethylation
along with double strand DNA breaks (DSBs) are likely to be
an unwanted consequence of SHM. It is not clear how efficient
are DNMTs (DNMT1 and DNMT3b are expressed in the GCBs
(15)] in remethylating aberrantly hypomethylated loci. There does
not seem to be a detectable loss of 5mC in the GCBs based on
high-performance liquid chromatography (HPLC) measurements
in isolated B cell fractions. Nevertheless, the methylation pro-
filing indicates that there is a locus-specific loss of methylation
in GCBs (15). DNMT1 localizes to the sites of DSBs and phos-
phoH2AX foci, and its absence results in increased number of
DSBs, making it a likely candidate to remethylate AID-dependent
demethylated loci (69). Global post-replicative remethylation of
DNA depends on association of DNMT1 with PCNA and replica-
tion machinery. In addition, DNMT1 has been shown to associate
with various transcription factors and remethylate various genes
during not only S phase, but also G1 and G2 phases of the cell
cycle (70, 71). Hervouet et al. also demonstrated that some genes
remained hemi-methylated when leaving S phase and showed a
delay in remethylation later in the cell cycle (70). How cell cycle
and proliferative rate of GCBs affect global and locus-specific
demethylation is an interesting question. It is conceivable that
faster proliferation with shorter cell cycle may result in accumula-
tion of hypomethylation. The extent of such passive demethylation
is likely to be limited due to the protective effect of Hayflick
limit of cell divisions in normal cells (72, 73). In cancer, on the
other hand, this stochastic accumulation of hypomethylation may
contribute to detectable levels of genomic hypomethylation. How-
ever, our data in diffuse large B cell lymphoma (DLBCL) cell
lines does not reveal different degrees of genome methylation in
cell lines with different duration of the cell cycle (unpublished
data).
Using microarray-based DNA methylation profiling of NBs
and GCBs (15), we demonstrated that hypomethylated loci
within GCBs were significantly associated with RGYW-like AID-
recognition motif (74) and CHIP-seq experiments identified AID-
binding sites (42), providing another line of indirect evidence for
the link between AID and DNA hypomethylation in B cells. On
the other hand, Fritz et al. performed ex vivo experiments using
Aicda−/−mice and reported that the absence of AID did not affect
the methylome of activated B cells generated from splenic CD43−
B cells stimulated with lipopolysaccharide (LPS), interleukin-(IL)-
4, and anti-CD40. However, the authors did not exclude that AID
could function as a DNA demethylase in vivo (63). Indeed, this ex
vivo system of mouse B cell activation is not equivalent to in vivo
GC reaction. For instance, the mutation rate in activated B cells is
one order of magnitude lower than in GCBs (41, 75, 76). In addi-
tion, Hogenbirk et al. profiled purified GCB from immunized mice
using MethylCap-Seq and failed to detect any difference in DNA
methylation between wt and Aicda−/− mice (77). Nevertheless, it
would be necessary to apply higher resolution genome-wide tech-
niques to definitely answer this question. A useful tool to prove the
demethylase function of AID in B cells would be a mouse model of
GC-specific overexpression of AID, since to date the only available
conditional AID-transgenic mice overexpress AID under the CD19
promoter, a molecule expressed in B cells from the early stages of
differentiation (78). Therefore, better tools and approaches are
necessary to elucidate the role of AID in the DNA demethylation
process that occurs in B cells during their transit through the GC
reaction (15).
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PROPOSED MECHANISMS OF ACTIVE DEMETHYLATION
In order to understand the link between deaminase activity of AID
and DNA demethylation, we will review the current state of knowl-
edge of the mechanisms involved in active DNA demethylation.
Flowering plants possess a set of DNA glycosylases (DEMETER,
ROS1, DML2, and DML3) capable of recognizing and remov-
ing 5mC in a discrete number of loci, such as imprinted genes
and silenced transgenes (79–81). Due to the lack of homologs
of 5mC DNA glycosylases in vertebrates, other mechanisms of
DNA demethylation have been proposed in mammals. It is well
established that the BER machinery, which restores nucleotide
lesions originated after base deamination, alkylation, or oxida-
tion (82), is involved in the process of active DNA demethylation
(83, 84). The most frequent lesion in DNA is uracil, which is
removed by members of the UDG family: UNG, thymine DNA
glycosylase (TDG), single-strand-selective monofunctional uracil-
DNA glycosylase 1 (SMUG1), and MBD4 (85). The first model
for 5mC demethylation was described in zebrafish embryos and
proposed that deamination of 5mC by AID generated a T:G
mismatch that was excised by MBD4, with the cooperation of
GADD45, and finally repaired to restore C (45). The formation
of a complex containing AID, GADD45, and a DNA glycosylase
was also observed in an independent study using HEK293 cells,
although the authors identified TDG as the glycosylase of the BER
machinery involved in demethylation (86). The discovery of the
base 5-hydroxymethyl-2′-deoxycytidine (5hmC) (87) as a result
of the 5mC oxidation by proteins of the (ten-eleven transloca-
tion) TET family (88) enabled the identification of other possible
mechanisms of active DNA demethylation (89). One report pro-
posed that the conversion of 5mC to 5hmC by TET1 initiated
an oxidative-deamination process mediated by the coordinated
action of AID/APOBEC proteins and BER pathway, which led to
DNA demethylation (90). 5hmC deamination by AID generated
5hmU, which was excised and repaired by the BER machinery. The
specific 5hmU DNA glycosylases were not identified, but subse-
quent experiments with TDG−/− mice suggested that TDG was
the DNA glycosylase responsible for the excision of 5hmU (or T)
after deamination by AID of 5hmC (or C) (86). This model of
active DNA demethylation involved the deamination of 5hmC to
5hmU by AID/APOBEC proteins, a step that was questioned later
on due to the voluminous size of the hydroxymethyl group (91).
The biochemical analysis of the AID enzymatic activity using a
ssDNA oligonucleotide deamination assay (ODA) (27) indicated
that AID could deaminate C and 5mC, but was unable to remove
the side chain at C5 position from 5hmC due to the size of the
hydroxyl group (91). In line with these results, Nabel et al. demon-
strated that the deamination activity of AID diminished with the
increasing size of the substituent at five position of C due to steric
hindrance (47). The rate of 5mC deamination was only 10% rel-
ative to unmethylated-C, and no activity was detected on 5hmC
in vitro. Therefore, if in vitro findings by Nabel et al. also apply
in vivo, the role of AID in direct demethylation of 5mC and 5hmC
may be limited. As an alternative, Petersen-Mahrt’s group has
recently proposed that methylated-Cs do not have to be directly
targeted by AID to be demethylated (92). Using an in vitro reso-
lution (IVR) assay consisting of a methylated plasmid containing
GAL4 DNA-binding sites and a GAL4-AID fusion protein com-
bined with xenopus laevis egg extracts-containing molecules of the
BER machinery, this study provides evidence for the activation
of different DNA repair pathways after AID-mediated deami-
nation. The short-patch-BER machinery restores only one base,
whereas the processive DNA polymerase pathways (long-patch-
BER or MMR) incorporate multiple nucleotides during the repair
process (82, 93, 94). In that last scenario, the deamination of C
(or 5mC) to U (or T) by AID would promote the activation of
a processive DNA polymerase, which would introduce from 2 to
12 nt in the case of the LP-BER (93), or up to 2 kb of ssDNA if
the MMR pathway is triggered (95). As a result, there would be
extensive demethylation along the section of DNA around the ini-
tial lesion and 5hmC demethylation would occur independently
of targeted AID deamination (92). However, the physiological
relevance of this model still needs to be confirmed. All these
proposed mechanisms of AID-mediated demethylation rely on
the lesion-induced activation of the DNA repair pathways. In all
scenarios, the deamination activity of AID introduces a modi-
fied base that is targeted by the repair machinery. SHM results
from recruitment of the error-prone short-patch BER-especially
in Ig genes, leading to a single nucleotide substitution, and a loss
of a “methylatable” C. The active and direct loss of methylation
is possible if AID deaminates 5mC to T. On the other hand, if
LP-BER or MMR are involved in repair, the outcome is more
marked demethylation that extends beyond the original single
nucleotide lesion (96). It remains unclear how AID is recruited
to its DNA targets. SHM is linked to transcription: AID requires
ssDNA to initiate the deamination of IgV regions (97). Regarding
AID partners, it has been demonstrated that stalled Pol II, Spt5,
and RPA are necessary for recruitment of AID to Ig and non-Ig
targets (98, 99). Duke et al. delineated that a combination of E-
box with YY1 and C/EBP-β binding sites targets AID in B cells
(100). However, it is not known if demethylation and SHM targets
are always the same. Hypothetically, the demethylation targets may
exceed the numbers of SHM targets due to successful repair, which
would leave the AID target site as mutation-free but demethy-
lated. Also, hypomethylated areas are located in introns, intergenic
regions and repeat elements rather than promoters, suggesting
a different targeting mechanism (46). In contrast, other studies
have proposed that active DNA demethylation does not involve
AID/APOBECs-mediated deamination, but it occurs through the
different intermediates generated after the successive oxidation
of 5hmC by TET proteins: 5-formyl-C (5fC) and 5-carboxyl-C
(5caC), which are excised by TDG and replaced by unmodified
cytosine (101, 102). Finally, it has been demonstrated recently
that TETs are able to oxidize T to 5hmU in mouse ESCs (103).
This finding unveils another possible mechanism of demethyla-
tion consisting of AID-mediated deamination of mC to T followed
by conversion of T to 5hmU by TET proteins. Based on the pre-
viously mentioned results, it seems reasonable to conclude that
both AID-dependent and TET-dependent mechanisms partici-
pate in the active demethylation of the genome (Figure 1). To
what extent they are interconnected or which one is preferen-
tially activated depending on the cell type needs to be further
investigated.
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FIGURE 1 | Schematic representation of the proposed mechanisms for
active DNA demethylation. DNMTs catalyze the methylation of cytosine
(C) to 5-methyl-C (5mC), which can be deaminated to thymine (T) by AID.
The generated mismatch can be repaired by the short-patch BER
machinery, restoring C, or by one of the processive repair pathways
(long-patch BER or MMR), leading to demethylation of a fragment of DNA.
This machinery involving processive DNA polymerases can also repair the
uracil:guanine (dU:dG) mismatches generated after C deamination to U. On
the other hand, TET-mediated hydroxylation of 5mC generates
5-hydroxymethyl-C (5hmC), which can be deaminated by AID/APOBECs to
5-hydroxymethyl-U (5hmU) and replaced by C through BER. 5hmC can be
further oxidized by TETs proteins to 5-formyl-C (5fC) and 5-carboxyl-C
(5caC), leading to activation of BER to restore C. Finally, another potential
mechanism of active DNA demethylation would involve 5mC deamination
to T and TET-mediated oxidation of T to 5hmU, which would be replaced by
C through BER, although this model has not been proven as yet.
DNA HYPOMETHYLATION AND CANCER
The question of AID activity, its possible link to DNA hypomethy-
lation and predisposition to cancer is a fundamental one. At the
moment, only a tenuous link exists between AID-induced SHM
and DNA hypomethylation in B cells and B cell lymphomas. There
is a large body of evidence though linking hypomethylation to can-
cer (70, 104, 105). Many subtypes of lymphomas reveal genome-
wide hypomethylation. Wahlfors et al. made an early observa-
tion that chronic lymphocytic leukemia (CLL) genome undergoes
global loss of methylation using digestion of genomic DNA with
isoschizomer enzymes HpaII and MspI, followed by validation
using HPLC (104). More recently, these findings were confirmed
by whole methylome sequencing studies, which revealed that aber-
rant hypomethylation was centered in repetitive sequences, like
ALU and LINES and were particularly pronounced in CLL with
TP53 mutations (106). A subset of DLBCLs also revealed loss
of DNA methylation, as demonstrated by Chambwe et al. (107).
Methylome interrogation in the follicular lymphoma (FL) cell line
RL and in CD19+ B cells using 454 sequencing technology (108)
revealed hypermethylation in the promoters, but hypomethylation
in intra- and intergenic areas of the genome.
DNA methylation patterns in all tissues and cell types are
a result of two main forces: deterministic patterning and sto-
chastic changes [reviewed in Ref. (109)]. Deterministic changes
in DNA methylation reflect the tissue-specific forces, which are
dependent on transcription factors and epigenetic factors that
reflect the tissue type and determine cellular identity. On the
other hand, the stochastic changes reflect the cell-to-cell vari-
ability, with individual cells at the same tissue and differentia-
tion stage displaying epigenetic heterogeneity. There are several
possible sources of stochastic variability: aging, ambient muta-
gens, oxidative damage, errors, and off-target activity of epi-
genetic enzymatic factors (110, 111). Several mechanisms have
been proposed to contribute to DNA hypomethylation in normal
development and disease, which to different degrees can explain
deterministic and stochastic DNA hypomethylation. One explana-
tion is a possible reduction of intracellular concentration of DNA
methyl donor S-adenosylmethionine (AdoMet) or an increased
concentration of the product of the reaction and its inhibitor
S-Adenosylhomocysteine (AdoHcy) (112). Methyl-deficient diet
has been shown to lead to AdoMet deficiency in a mouse model
(113), but has not been proven to contribute to carcinogenesis
in humans. Another logical explanation for DNA hypomethy-
lation would be the decreased activity of DNMTs or increased
activity of demethylases. Published observations in tumors and
normal development suggest that hypomethylation does not cor-
relate with decreased expression of DNMTs or their mutations
(114–116). On the other hand, active demethylation can take
place either by the action of yet unidentified demethylases or
through DNA repair process. Enzymatic demethylation is not
favored because of the stability of the chemical bond. Ram-
chandani et al. reported the biochemical purification of a DNA
demethylase from tumor cells (117). The same group demon-
strated that the rate limiting step in the reaction is initiation
of demethylation, which is sequence specific and progresses in
a processive manner sliding along the DNA and demethylating
CpGs in cis position (118). MBD2 was demonstrated to pos-
sess demethylase activity in biochemical in vitro experiments
and in solid cancers, but its function as demethylase remains
controversial (119, 120). Another possibility is modification of
DNA nucleotides by deaminases resulting in eventual excision
and repair of that nucleotide and loss of methylation. AID is
the key candidate for this mechanism of demethylation, as dis-
cussed before. AID is known to contribute to chromosomal
instability and induce chromosomal translocations by inducing
DSBs (see below). B lymphocytes from IgκAID-transgenic mice
showed increased number of chromosomal translocations (6%
of cells) and increased frequency of DNA breaks (8% of cells)
(121). The contribution of hypomethylation to AID-dependent
genomic instability has not been addressed and warrants further
investigation.
The biological effect of DNA hypomethylation is its contribu-
tion to reactivation of transposable elements, activation of onco-
genes, and increased chromosomal fragility, as demonstrated ele-
gantly by Gaudet et al. in experiments with hypomorphic DNMT1
mice (122, 123). Mice with low DNMT1 expression at 10% of
wild type level demonstrated marked reduction in genome-wide
DNA methylation and revealed significant increase in genomic
instability and activation of proto-oncogenes, like c-Myc (124).
The maintenance of methylation in mammalian cells is accom-
plished by DNMTs, particularly DNMT1 and its complex with
PCNA and UHFR1. Disruption of this complex results in global
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hypomethylation and serves as a biomarker of poor prognosis in
GBM tumors (125).
ROLE OF AID IN LYMPHOMAGENESIS
AID is expressed in half of Burkitt lymphomas (BLs), 30% DLBCLs
and 25% FLs, and is absent in B cell precursor lymphoblas-
tic leukemia and mantle cell lymphomas (126, 127). Due to its
DNA mutator capacity, AID activity represents a potential risk
for genomic instability. It is clear that AID can introduce point
mutations in Ig and non-Ig genes and also induce chromosome
translocations involving oncogenes, which contribute to the devel-
opment of B cell neoplasms (128). Pasqualucci et al. found that
proto-oncogenes such as PIM1,MYC,RHOH /TTF, and PAX5 were
aberrantly mutated in more than 50% of the DLBCLs cases ana-
lyzed, probably due to failure of the SHM pathway (129). In addi-
tion, chromosomal translocations are frequent in lymphomas and
myelomas, including DLBCLs, BLs, multiple myeloma, and mouse
plasmacytoma (130, 131). Specifically, translocations between c-
MYC and the Ig CH genes (c-MYC/IgH ) are a hallmark of BLs and
were demonstrated to be AID-dependent, since AID-deficiency
eliminated the presence of canonical cMyc translocations in BCL6
or Bcl-xL transgenic mice (132, 133), although the frequency of
DSBs was lower in c-Myc than in IgH (76). Moreover, mutations
in the anti-apoptotic protein BCL2 are frequent in DLBCLs and
are enriched in the AID-binding motif WRCY (134).
Multiple mouse models have been established to study lym-
phomagenesis in vivo, and more specifically to clarify the role
of AID in the induction and development of B cell neoplasms.
Experiments with IµHABCL6 transgenic mice, which develop
lymphomas due to the deregulated expression of the transcrip-
tional repressor BCL6 under the control of the IgH Iµ promoter
(135), demonstrated that AID had a role in lymphomagene-
sis (136). AID-deficiency in IµHABCL6 background prevented
the formation of GC-derived lymphomas. This effect was not
observed when crossing Aicda−/− mice with other lymphoma-
prone mouse models such as λMYC mice, which develop pre-GC-
derived lymphomas, or λMYC/IµHABCL6 mice, characterized
by the formation of post-GC-derived malignancies. The same
report showed that ex vivo stimulated B cells from IµHABCL6
mice presented a high number of c-Myc/IgH translocations, which
were not present in activated IµHABCL6/Aicda−/− cells. The
authors proposed that AID-mediated translocations contributed
to lymphoma formation (136). Another study reported that AID
activity determined the frequency of lymphocytes with c-Myc/IgH
translocations, influencing the incidence of B cell tumor develop-
ment in a mouse model of plasmacytoma (137). An independent
group demonstrated the link between AID-mediated chromo-
some translocations and mature B cell lymphomas using another
transgenic mouse strain, which expressed AID under the control
regulatory elements of the light chain Igκ (121). In this exper-
imental design, deregulated AID expression generated DSBs in
the genome of B cells, inducing c-Myc/IgH chromosome translo-
cations. Nonetheless, AID overexpression was not sufficient to
drive B cell lymphomagenesis, requiring the concomitant loss of
the tumor suppressor p53 in that model (121). The generation
of a transgenic mouse strain with sporadic c-Myc activation in
GCBs (Vk*MYC), which led to a multiple myeloma phenotype,
indicated that AID-mediated SHM was required for the aberrant c-
Myc expression and the subsequent plasma cells expansion (138).
Constitutive expression of AID using a transgenic mouse model,
which expresses AID under the control of the ubiquitous CAG
promoter, led to T cell lymphomas containing no translocations
but abundant point mutations in c-Myc and the TCR genes (139).
Bone marrow transplantation experiments with AID-transduced
cells also resulted in the development of T-lymphomas, with fre-
quent point mutations in Notch1, PTEN, and c-Myc. Noteworthy,
some of the mice presented B-lymphomas after transplantation.
Pax5 and Ebf1 were mutated in these B cell-derived malignan-
cies and no chromosome translocations were found (140). The
aforementioned mouse models proposed different mechanisms
of AID-mediated genomic instability, focused on the analysis of
somatic mutations or translocations involving proto-oncogenes
generated as a consequence of the deaminase activity of AID.
Intriguingly, the role of AID activity in the epigenetic stability
of the genome and its implication in lymphomagenesis remain
largely unexplored. De et al. (141) analyzed the DNA methylation
patterning in three subtypes of primary lymphomas: FL, GCB–
DLBCL, and ABC–DLBCL (142), which differs in their level of
aggressiveness (FL<GCB–DLBCL<ABC–DLBCL). This study
demonstrated that normal GCBs presented higher level of epi-
genetic heterogeneity than NBs, and also that inter-sample and
intra-sample methylation heterogeneity increased with lymphoma
aggressiveness, correlating with adverse outcome (141). Trying to
discover the cause for the abnormal DNA methylation patterns
in B cell lymphomas, the authors found that the promoters of
the targets of BCL6 and EZH2 showed an aberrant hypermethy-
lated status compared to normal B cells. On the contrary, AID
target genes presented an abnormal promoter hypomethylation.
In addition, the expression level of AID was significantly correlated
with genome-wide aberrant hypomethylation (141). This result,
along with the established role of AID in active DNA demethyla-
tion during normal development and also with the significantly
higher hypomethylation in GCBs compared to NBs in regions
enriched for the putative AID-binding site RGYW, suggests an
epigenetic role for AID during GC transit of normal B cells and
in GC-derived lymphomagenesis. Such a role needs to be formally
proven and will have great implications on our understanding of
B cell biology.
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